Primary Prevention with Statins: How Much Risk Reduction Do People Expect?

Why It Matters

The study shows that perceived modest benefits deter statin uptake, affecting primary-prevention strategies and prompting clinicians to refine risk communication to improve adherence.

Key Takeaways

• Most low-risk individuals reject statins despite zero-risk promise
• Moderate-risk patients consider statins but balk at modest benefit
• High-risk respondents often decline when benefit is only 2.5-5%
• Study surveyed 500 statin-naïve adults across three risk levels
• Patient autonomy emphasized; clinicians should continue risk-benefit discussions

Summary

The video discusses a JAMA Internal Medicine study examining how individuals perceive the benefit of statins for primary prevention of cardiovascular disease, using hypothetical 10-year risk scenarios.

Researchers surveyed roughly 500 statin-naïve participants, presenting three risk levels—2.5 % (low), 10 % (moderate), and 20 % (high). The majority at the low-risk tier would not take a statin even if it eliminated risk entirely. At moderate and high risk, willingness rose, but once participants learned the absolute risk reduction would be only 2.5–5 %, many reversed their decision.

The narrator illustrates the findings with his mother-in-law, who had a calculated 13 % 10-year risk. Although initially open to therapy, she declined after hearing the modest 2.5–5 % benefit, stating the small gain did not justify medication side effects or inconvenience.

The results highlight a gap between guideline recommendations and patient expectations, underscoring the need for clinicians to communicate absolute risk reductions clearly and respect patient autonomy while revisiting the conversation over time.

Original Description

NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD, describes a recent survey of ≈500 people who had no prior statin use to determine their willingness to take statins based on their hypothetical levels of 10-year risk.

Read the context and comment at clinician.nejm.org.

#cardiology #lipids #clinicalmedicine